Chemotherapy Doublet — Competitive Intelligence Brief

Chemotherapy Doublet (Chemotherapy Doublet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy. Area: Oncology.

phase 2 Chemotherapy Oncology Small molecule

Target snapshot

Chemotherapy Doublet (Chemotherapy Doublet) — BeiGene. Chemotherapy agents work by interfering with DNA replication and cell division, leading to cell death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Chemotherapy Doublet TARGET	Chemotherapy Doublet	BeiGene	phase 2	Chemotherapy
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
Bleomycin + Fibrovein	Bleomycin + Fibrovein	Oslo University Hospital	marketed	Chemotherapy agent with hemostatic adjuvant	DNA (bleomycin); fibrin polymerization (fibrovein)
Gemcitabine-Cisplatin chemotherapy	Gemcitabine-Cisplatin chemotherapy	Simcere Pharmaceutical Co., Ltd	marketed	Chemotherapy combination (nucleoside analog + platinum agent)	DNA (multiple targets including ribonucleotide reductase inhibition and DNA cross-linking)
Irinotecan, 5FU, leucovorin	Irinotecan, 5FU, leucovorin	Asan Medical Center	marketed	Chemotherapy combination (topoisomerase I inhibitor + antimetabolite)	Topoisomerase I; thymidylate synthase
Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone	Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone	Technische Universität Dresden	marketed	Combination chemotherapy (nucleoside analog + topoisomerase II inhibitors)	DNA polymerase (cytarabine); Topoisomerase II (amsacrine, mitoxantrone)
TAC chemotherapy	TAC chemotherapy	Agendia	marketed	Chemotherapy regimen (combination)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy class)

1. University Hospital, Rouen · 2 drugs in this class
2. Sun Yat-sen University · 2 drugs in this class
3. Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
4. Beijing Biostar Pharmaceuticals Co., Ltd. · 1 drug in this class
5. Delcath Systems Inc. · 1 drug in this class
6. Ludwig-Maximilians - University of Munich · 1 drug in this class
7. Prof. Dr. med. Claus Rödel · 1 drug in this class
8. Prothena Biosciences Ltd. · 1 drug in this class
9. Seoul National University Hospital · 1 drug in this class
10. Shanghai Zhongshan Hospital · 1 drug in this class